Ensysce Biosciences (OTCMKTS:ENSC) Stock Price Down 5.1%

Ensysce Biosciences, Inc. (OTCMKTS:ENSCGet Rating)’s share price traded down 5.1% on Wednesday . The stock traded as low as $2.00 and last traded at $2.06. 123,537 shares changed hands during mid-day trading, an increase of 27% from the average session volume of 96,920 shares. The stock had previously closed at $2.17.

Ensysce Biosciences Price Performance

The firm’s 50 day simple moving average is $6.48 and its two-hundred day simple moving average is $9.96.

Ensysce Biosciences (OTCMKTS:ENSCGet Rating) last released its quarterly earnings results on Thursday, August 11th. The company reported ($4.80) EPS for the quarter, missing analysts’ consensus estimates of ($4.20) by ($0.60). The business had revenue of $0.21 million during the quarter, compared to analyst estimates of $1.00 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in shares of Ensysce Biosciences in the 1st quarter worth approximately $28,000. Powell Investment Advisors LLC bought a new position in shares of Ensysce Biosciences in the 1st quarter worth approximately $57,000. BlackRock Inc. raised its position in shares of Ensysce Biosciences by 41,654.0% in the 1st quarter. BlackRock Inc. now owns 234,240 shares of the company’s stock worth $267,000 after acquiring an additional 233,679 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Ensysce Biosciences in the 1st quarter worth approximately $328,000. Finally, Anson Funds Management LP bought a new position in shares of Ensysce Biosciences in the 1st quarter worth approximately $2,138,000.

Ensysce Biosciences Company Profile

(Get Rating)

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology.

See Also

Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.